Catheter Precision (VTAK) Fundamental Analysis: Revenue, Earnings & Valuation

1.02 / 10

Underperform

Fundamentally, VTAK is underperforming with a 1/10 score. Key ratios are negative: ROA –24.2%, annual net profit margin –48.4%, and operating cash‑flow –2079%. Only net profit/total profit shows a modest positive rating. Overall, fundamentals are guarded.

Analysis Checks(0/6)

ROA (%)

Value-24.19

Score0/3

Weight21.31%

1M Return-6.58%

Net cash flow from operating activities / Operating revenue (%)

Value-2079.43

Score0/3

Weight21.36%

1M Return-6.63%

Annualized net profit margin on total assets (%)

Value-48.39

Score0/3

Weight21.31%

1M Return-6.58%

EBIT / Total operating revenue (%)

Value-3958.29

Score1/3

Weight3.59%

1M Return-0.83%

Net profit / Total operating revenue (%)

Value-3940.00

Score0/3

Weight21.75%

1M Return-6.68%

Net profit / Total profit (%)

Value100.00

Score1/3

Weight10.67%

1M Return-2.39%

Is VTAK fundamentally strong?

VTAK scores 1.02/10 on fundamentals and holds a Premium valuation at present. Backed by its -186.69% ROE, -2160.56% net margin, -0.15 P/E ratio, 0.38 P/B ratio, and 87.47% earnings growth, these metrics solidify its Underperform investment rating.